左乙拉西坦联合替莫唑胺作用于胶质瘤细胞的体外研究

摘要

Objective The antitumor effect of levetiracetam (LEV) combined with temozolomide (TMZ) was investigated in glioma cell lines.Methods The cell proliferation with cell counting kit-8 (CCK-8) assay was performed in two O6-methylguanine DNA methyltransferase (MGMT) positive cell lines (T98G and U138) and two other MGMT negative cell lines (SKMG-4 and U87).The cells were treated with LEV and TMZ alone or in combination.Results LEV inhibited the proliferation of glioma cell hnes but did not reach the therapeutic effect,especially in U87.The 50％ inhibitory concentration (IC50) of TMZ was significantly decreased in cell lines (T98G,U138 and SKMG-4,P ＜ 0.05) which were treated with TMZ and LEV with no significant changes in U87 (P ＞ 0.05).Conclusion LEV may inhibit the proliferation of glioma cell lines (both MGMT-positive and MGMT-negative) and also sensitizes the cell lines (T98G,U138 and SKMG-4,but not U87) to TMZ.%目的 探讨左乙拉西坦(LEV)联合替莫唑胺(TMZ)作用于胶质瘤细胞的效果.方法 采用细胞计数试剂(CCK-8)检测并计算左乙拉西坦单药或联合替莫唑胺对人胶质瘤O6-甲基鸟嘌呤DNA甲基转移酶(MGMT)阳性细胞系(T98G、U138)、MGMT阴性细胞系(SKMG-4、U87)的抑制率和替莫唑胺的半抑制浓度(IC50).结果 LEV单药作用于胶质瘤细胞系,多表现出一定程度的肿瘤抑制作用,但达不到治疗作用,特别对U87的抑制作用更弱.LEV联合TMZ作用T98G、U138和SKMG-4后,TMZ的IC50均有不同程度下降(P＜0.05),但在U87上差异无统计学意义(P＞0.05).结论 左乙拉西坦可抑制胶质瘤细胞(MGMT阳性和阴性)增殖,并可增敏替莫唑胺对T98G、U138和SKMG-4的疗效,但对U87细胞没有增敏作用.